Sylvio is the Senior Scientific Director of Adebiotech. He will be the chairman of the Conference on behalf of Adebiotech.
Pauline has a Ph.D. in biological function engineering and an engineering degree in project management. After 10 years of experience in financing innovation in various structures, Pauline joined Ingredia as scientific and innovation manager on bioactives. Ingredia carries out pre-clinical and clinical trials for all its bioactive ingredients, the alternative to animal experimentations is naturally a subject that concerns us.
Organic Chemist, graduated from Orsay-Paris XI University in 1988 (nowadays Paris-Saclay), Christophe DINI initiated his carrier as medicinal chemist at Roussel Uclaf, then he successively became Laboratory Head, then Group Leader at Sanofi-Aventis. In parallel he was missioned as Project Leader in Anti-infective and Oncology for projects spanning from target identification to preclinical development.
Thereafter, in 2004, he co-founded Oroxcell, a CRO specialized in DMPK studies, along with developing its own portfolio of innovative therapeutics for of pain treatment. In 2015, while taking the lead of the company, he refocused Oroxcell activities towards In Vitro tests and more precisely by incorporating a suite of in chemico and 3D human epithelia-based model to support the ineluctable evolution towards alternative methods to animal use.
Today a fair number of these methods serve the regulatory safety assessment of substances issued from for pharma, cosmetic, medical device and chemical industries, and therefore endorsed in lieu of animal models.
Maxime is an entrepreneur with an engineering degree and an Executive MBA. He has extensive expertise in pharmaceutical R&D, biotechnology, strategy and business development. Maxime began his career at INSERM. In 2002, he joined Sanofi where he led numerous drug developments as team leader, international project manager and pharmacologist scientist. Maxime co-founded Vibiosphen in 2014 and Enterosys in 2017.
Thibault Honegger is the President, Chief Scientific Officer and co-founder of NETRI. He graduated from the Ecole Centrale of Nantes (France), and received his MS degree in Biotechnologies from Grenoble Alpes University and his PhD degree in Electrical Engineering from LTM (CNRS/ Grenoble Alpes University) on 3D electrokinetic handling of cancer cells and particles in laboratory on chip devices. He was a post-doctoral fellow at the Voldman lab at MIT for two years where he developed and investigated axonal guidance using contactless forces to design neural circuits. He then joined CNRS as a principal investigator in Grenoble to lead the microfluidics neuro-engineering team. In 2018, he co-founded NETRI. He co-authored 25 peer-reviewed research papers, 6 granted patents and 1 book chapter. He is a member of the editor board of IET NanoBioTechnologies. He founded and chairs the Neurofluidics conference: Neuroscience & Microfluidics. He co-founded Peerus in 2015, a web application for scientific paper monitoring, Linkio in 2015 and Smart Force Technologies in 2016.
Danielle Lando was awarded her PhD by the Institut Pasteur for her research in virology. She led a career in the pharmaceutical industry as a researcher in cellular and molecular pharmacology before she was put in charge of biotechnologies within the Roussel-Uclaf group, now called Aventis. She has striven for drawing her company closer to the academic world by promoting collaborative projects. She was a member of the CNRS National Committee from 1995 to 2000.
She has worked as a volunteer scientist with Adebiotech since 2001 and is currently the Vice-Chairwoman of Adebiotech.
Involved for several years in development and promotion of in vitro toxicology assays based on reconstructed human tissues.
After a PhD in neuroscience at the French National Institute of Health and Medical Research (INSERM) he held a temporary teaching position at the university of Tours (France). He joined L’Oréal R&I in 2000 at the Life Science Research Center where he was involved in development and implementation of computerized tools for alternative to animal approaches in toxicology (results database, expert systems).
In 2004 he was appointed to scientific communication on alternative methods to animal testing and tissue engineering.
In 2011 he joined EPISKIN, a subsidiary of L’Oréal, dedicated to development and production of reconstructed human epithelia. As Scientific Director, he has been involved in several development projects that led to the introduction of new models and methods to the market. He developed the EPISKIN Academy program to promote the dissemination of alternative methods through education and training and to relay EPISKIN commitments to 3Rs.
Involved for several years in biocompatibility of medical devices he is Chairman of the French AFNOR S92J commission and convenior of the WG8 skin irritation and sensitization of the ISO/TC194 for biocompatibility of medical devices. He is also L’Oreal R&I Research associate and member of the advisory council of the Indian Society for Alternatives to Animal Experiments (SAAE)
Rozenn RAVALLEC is a professor at the University of Lille, and leads a team in the UMRT INRAE BioEcoAgro. She has almost 20 years of expertise in the development of agri-food co-products and her research focuses more particularly on the biological activity of peptides generated during gastrointestinal digestion and their interactions with the intestinal environment. It is also responsible for a platform allowing the screening of biological activities. This platform consists of the implementation of assay techniques but also of methodologies for understanding the mechanisms of action of peptides, in particular anti-stress (opioid), antihypertensive (ACE inhibitor), involved in the regulation of metabolism. energy, (obesity, diabetes) or even anti-inflammatory. This platform also seeks to measure the cytotoxic impacts of these active molecules. She is involved in the European BBI BIOSMART project on the design of intelligent bio-sourced packaging for better preservation of food quality, co-director of a joint team with the company Ingredia (AlLInPep) and co-director of the laboratory international associate (LAI) on the bioproduction of natural antimicrobials (LIAAN) with INAF in Quebec.
